An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 10 Jan 2018 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
- 10 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2018.
- 28 Oct 2016 Planned number of patients changed from 82 to 72.